Crystallin: Research & Evidence
Early-Stage ResearchPublished research, clinical trial data, and evidence grading for Crystallin across studied indications.
Back to Crystallin overviewResearch Summary
Crystallin (HSPB5/alpha-crystallin) is studied exclusively as a biomarker, not as a therapeutic. Over 15 human studies have measured crystallin levels in lens tissue, aqueous humor, tears, serum, and retinal samples as diagnostic markers for cataracts, glaucoma, diabetic retinopathy, dry eye, and aging. However, zero human therapeutic trials exist — no one has ever administered crystallin as a drug. All therapeutic-oriented research (chaperone therapy, retinal protection) remains in animal models using gene therapy vectors (AAV), not protein administration. No pharmaceutical development program has been initiated.
Evidence by Indication (3 indications)
| Indication | Tier | Trials | Summary |
|---|---|---|---|
| Cataract biomarker | Tier C | 0 | Validated as diagnostic biomarker, not a therapeutic |
| Retinal protection | Tier D | 0 | Animal gene therapy studies only — no human trials |
| Anti-aging therapeutic | Tier D | 0 | No therapeutic development — biomarker research only |
Graded using our evidence tier methodology.
Higher score = larger gap between therapeutic potential and available clinical evidence.
Citations (3 sources)
- 1. Crystallin in lens biology and pathology Review
Andley UP (2007), Progress in Retinal and Eye Research
- 2. Crystallin changes in human cataractous lenses Study
Pasupuleti N, et al. (2013), Molecular Vision
- 3. Alpha-crystallin overexpression protects retina in mouse model Study
Yaung J, et al. (2007), Experimental Eye Research